Tumor necrosis factor-related apoptosis-inducing ligandreceptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)-induced celldeath signaling. TRAIL-R1 and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL). Because TRAIL/TRAIL receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-R1 and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL. In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-R1 gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-R1 gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-R1 and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-R1 and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R1 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL. Oncogene (2001) 20, 399 ± 403.
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Keywords: mutation; TRAIL-receptor 1; TRAILreceptor 2; non-Hodgkin's lymphoma Apoptosis is a fundamental biochemical cell-death pathway essential for normal tissue homeostasis, cellular dierentiation and development (Nagata, 1997) . Several members of tumor necrosis factor family such as tumor necrosis factor (TNF)-a, Fas ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) have been shown to induce apoptosis in susceptible cells MacFarlane et al., 1997; Nagata, 1997; Pan et al., 1997; Schneider et al., 1997; Walczac et al., 1997) . TRAIL can induce apoptosis by interaction with two receptors, referred to as TRAIL-receptor 1 (TRAIL-R1) and TRAILreceptor 2 (TRAIL-R2) MacFarlane et al., 1997; Schneider et al., 1997) . These receptors were found to be widely expressed in normal and neoplastic cells Keane et al., 1999; MacFarlane et al., 1997; Mori et al., 1999; Sheridan et al., 1997; Thomas and Hersey, 1998; Zhang et al., 1999) , but the expression of these proteins do not necessarily predict susceptibility to killing . This can re¯ect the presence of inhibiting mechanisms of TRAIL-induced apoptosis and blockade of TRAILinduced apoptosis may lead to the loss of its apoptotic function, and prolong the survival of aected cells.
Dysregulation of normal apoptotic mechanisms provides a growth advantage to cancer cells (Nagata, 1997) . The apoptotic pathway of Fas, one of the TNF receptor family members, is frequently blocked by several mechanisms in cancer cells, one of which is Fas gene mutation (Grùnbaek et al., 1998; Lee et al., 1999b,c; Shin et al., 1999) . Interestingly, the Fas mutations have been detected in several types of human cancers with frequent allelic losses of chromosome 10q24 where the gene resides (Lee et al., 1999b,c; Shin et al., 1999) . Therefore, it can be hypothesized that other members of TNF receptor family are mutated in the cancers with frequent allelic losses at the chromosome where each TNF receptor family gene resides.
Both TRAIL-R1 and TRAIL-R2 genes were mapped to chromosome 8p21-22 (MacFarlane et al., 1997; Marsters et al., 1997) . Allelic losses of the chromosome 8p21-22 have been reported as a frequent event in Oncogene (2001) (El-Naggar et al., 1998; Emi et al., 1992; Kagan et al., 1995; Mitelman et al., 1997; Monni et al., 1996; Wistuba et al., 1999; Yaremoko et al., 1996) . These data strongly indicate that the chromosome 8p21-22 may harbor one or more tumor suppressor genes and suggest that TRAIL-R1 and TRAIL-R2 genes might be the candidate tumor suppressor genes in this region. To date, mutations of TRAIL-R2 gene have been reported in head and neck cancer (Pai et al., 1998) and non-small cell lung cancer (Lee et al., 1999a) , while mutation of TRAIL-R1 gene has not yet been reported in any human tumors. In human NHL, frequent allelic losses involving the chromosome 8p21-22 region have been detected (Mitelman et al., 1997; Monni et al., 1996) . However, the mutation of candidate tumor suppressor genes at this region has not yet been reported in NHL.
TRAIL/TRAIL receptor system is involved in mechanism for the induction of lymphocyte apoptosis during immune regulation (Mariani and Krammer, 1998a,b; Martinez-Lorenzo et al., 1998) . However, in malignant lymphoid cells, most of the tumor cells are resistant to TRAIL-induced apoptosis (Snell et al., 1997) . Therefore, we hypothesized that the mutation of TRAIL-R1 and TRAIL-R2 may be one of the possible mechanisms of TRAIL resistance in NHL and that the mutation of TRAIL-R1 and TRAIL-R2 may be relevant to the loss of 8p21-22 in the NHL. In the present study, in order to explore these possibilities, we analysed a series of 117 NHLs for the detection of somatic mutations of TRAIL-R1 and TRAIL-R2 genes.
Formalin-®xed and paran-embedded tissues of human NHL were obtained from 117 patients. These samples were stained with hematoxylin-eosin, examined by immunohistology, and classi®ed according to the Revised European-American Lymphoma (REAL) classi®cation (Harris et al., 1994) . The NHLs analysed consisted of seven B-cell small lymphocytic lymphomas, three mantle cell lymphomas, four follicular lymphomas, 23 MALT-type lymphomas (14 high grade and nine low grade), 46 diuse large B-cell lymphomas, four precursor T-lymphoblastic lymphomas, one T-cell chronic lymphocytic leukemia, 14 peripheral T-cell lymphomas, unclassi®ed, 14 angiocentric lymphomas and one intestinal T-cell lymphoma. Through the microdissection technique, we selectively procured tumor cells and corresponding normal cells from histological sections of 117 NHLs as shown previously (Lee et al., 1998 (Lee et al., , 1999b Shin et al., 1999) . Genomic DNA was isolated and analysed for mutations and allelic deletions of the TRAIL-R1 and TRAIL-R2 genes by polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. We have analysed the entire coding region and all splice sites of TRAIL-R2 gene, while we have analysed only the death domain of TRAIL-R1 gene, because the genomic structure of this gene is not yet known.
SSCP analysis identi®ed eight aberrant bands. Enrichment and direct sequence analysis of these aberrantly migrating bands led to the identi®cation of TRAIL-R1 and TRAIL-R2 mutations in eight of the samples (6.8%) (Tables 1 and 2; Figure 1 ). Among the eight mutations, two mutations were detected in TRAIL-R1 and the remaining six mutations were detected in TRAIL-R2. The mutations consisted of seven missense mutations and one nonsense mutation (Tables 1 and 2 ). All of the two TRAIL-R1 mutations and four of the six TRAIL-R2 mutations were identi®ed within the death domains, whereas the two remaining mutations of TRAIL-R2 was identi®ed just Numbering of cDNA of TRAIL-R1 was done in respect to the ATG start codon according to Pan et al., 1997 outside of the death domain. None of the corresponding normal samples showed evidence of mutations by SSCP (Figure 1a,b,c) , indicating the mutations detected in the NHL specimens had risen somatically.
Two (cases 42 and 99) of the ®ve missense mutations detected in TRAIL-R2 showed an identical C to T transition at 1087 bp in unrelated patients and this mutation would result in the substitution of Leu to Phe at codon 363 ( Figure 1 ; Table 2 ). The remaining missense mutations of TRAIL-R2 aected codons 367, 416 and 435. The nonsense mutation detected in TRAIL-R2 showed a point mutation introducing premature termination signal at codon 340 ( Figure  1c,f) . The two missense mutations of TRAIL-R1 aected codons 376 and 382 (Table 1) . We repeated the experiments three times, including tissue microdissection, PCR, SSCP and sequencing analysis to ensure the speci®city of the results, and found that the data were consistent (data not shown). As for the relationship between the histologic types and the TRAIL-R1 and TRAIL-R2 gene mutations, the tumors with the mutations consisted of ®ve diuse large B-cell lymphomas, one peripheral T-cell lymphoma and two high-grade musosa-associated lymphoid tissue (MALT)-type lymphomas (Tables 1 and 2 ). Although ®ve of the eight mutations of TRAIL-R1 and TRAIL-R2 (71%) were observed in diuse large B-cell lymphoma, it was not statistically signi®cant (Fisher's exact test, P40.05).
Because one bi-allelic polymorphism at nucleotide position 1322 A/G or TRAIL-R1 (Kim et al., 2000) and four at nucleotide positions 95 T/C (exon 1), 200 T/C (exon 2), 572 C/T (exon 5) and 662 C/T (exon 5) of TRAIL-R2 gene (Arai et al., 1998) are known, SSCP analysis at these polymorphic sites was used to analyse the second allele status in the eight tumors carrying TRAIL-R1 or TRAIL-R2 mutations. Four of the six patients with the TRAIL-R2 mutations were heterozygous for one of the four intragenic polymorphisms, allowing evaluation of allelic loss in their tumors by SSCP analysis (Table 2 and Figure 1g) . Two of them (50%) (cases 42 and 59) showed evidence of allelic loss, while the other two cases (cases 98 and 99) showed evidence of retention of heterozygosity (Figure 1g ). The two patients with TRAIL-R1 mutations were homozygous and we were not able to analyse the allelic status of the tumors (Table 1 ). The aim of this study was to detect TRAIL-R1 and TRAIL-R2 gene alterations, one of the possible mechanisms that may mediate TRAIL resistance in NHL in vivo. Although we do not actually know whether the NHLs analysed in the present study were resistant to TRAIL-induced apoptosis in vivo, there have been some data that support the idea that these tumors may be resistant to TRAIL-induced apoptosis. For example, majority of NHL cell lines and primary NHL cells were reported to be resistant against TRAIL-induced apoptosis (Snell et al., 1997) . Also, in the present study, we found that 6.8% of the NHL samples had TRAIL-R1 or TRAIL-R2 mutations. These data suggested that human NHL may have dysregulation in TRAIL-induced signaling Figure 1 Mutations and deletions of TRAIL-R1 and TRAIL-R2 genes in the NHLs. Genomic DNA each from normal cells or tumor cells was ampli®ed with 15 primer pairs covering the entire coding region (9 exons) of TRAIL-R2 gene, which were the same primers described by Arai et al. (1998) . TRAIL-R1 gene was ampli®ed with two primer pairs covering the death domain. The primers for TRAIL-R1 death domain were designed with the program Oligo (National Biosciences, Plymouth, MN, USA) using sequences obtained from GenBank (accession No. U90875) and the primer sequences were as follows: (a) pathway and that TRAIL-R1 and TRAIL-R2 mutations may be responsible to such dysregulation at least in partial.
Although functional studies have not yet been performed, most or all of the mutations identi®ed in the present study are likely to disrupt or alter the normal function of TRAIL receptors. To date, TRAIL-R2 gene mutations have been reported in two cases of head and neck cancer and 12 cases of non-small cell lung cancer. Most of those mutations were detected in the death domain (Lee et al., 1999a; Pai et al., 1998) . The death domain is evolutionarily highly conserved and is shown to be necessary for the transduction of an apoptotic signal MacFarlane et al., 1997; Nagata, 1997; Schneider et al., 1997 ). In the current study, six of the TRAIL-R1 and TRAIL-R2 gene mutations were identi®ed in this conserved area and one nonsense mutation of TRAIL-R2 is predicted to cause premature termination of protein synthesis before the death domain, suggesting that these mutations might disrupt TRAIL-induced death signaling.
Binding of TRAIL to TRAIL-R1 or TRAIL-R2 induces trimerization of TRAIL-R1 or TRAIL-R2, and FADD/MORT-1 binds to the trimerized TRAIL-R1 or TRAIL-R2 death domains (Bodmer et al., 2000) . Then, FADD/MORT-1 acts as an adaptor molecule by recruiting caspase 8, which initiates a proteolytic cascade involving other caspases that eventually lead to cell death by apoptosis (Bodmer et al., 2000) . In the present study, two TRAIL-R2 gene mutations (cases 98 and 99) seemed to be hemizygous mutations without allelic deletion (Table 2 ) and this suggests dominant negative eect. In contrast, cases 42 and 59 showed loss of heterozygosity (LOH) at one of the intragenic polymorphic sites (Table 2) , indicating potential biallelic inactivation of the TRAIL-R2 gene in this case. But the functional dierence between mono-allelic and bi-allelic inactivation of TRAIL-R2 alterations in the tumorigenesis of NHL remains unknown at this stage.
Previous LOH and karyotypic studies have suggested that a putative tumor suppressor gene at chromosome 8p21-22 may be involved in the development of NHL (Mitelman et al., 1997; Monni et al., 1996) . Several candidate tumor suppressor genes of this region, including platelet derived growth factor-receptor-B-like tumor suppressor gene and N33 gene have been identi®ed (Fujiwar et al., 1995; MacGrogan et al., 1996) . However, mutational analysis of these genes in NHL has not yet been reported. Whether TRAIL-R1 or TRAIL-R2 is such a tumor suppressor is unknown at this time, but its function as a death receptor would be consistent with the tumor suppressor function. Therefore, the demonstration of TRAIL-R1 and TRAIL-R2 gene mutations in the NHL in this study suggest that TRAIL receptor gene may be one of the tumor suppressor genes at chromosome 8p21-22 and that TRAIL receptor gene mutations may be involved in the development of NHL.
